free acid

IQ-1S free acid (IQ-1S) is an effective and specific c-Jun N-Terminal Kinase Inhibitor. IQ-1S inhibits murine delayed-type hypersensitivity. IQ-1S can reduce inflammation and cartilage loss associated with CIA and can serve as a small-molecule modulator for mechanistic studies of JNK function in rheumatoid arthritis. IQ-1S is highly specific for JNK and that its neutral form is the most abundant species at physiologic pH.

Cefpodoxime (free acid) is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis.

4-Methylumbelliferyl-α-L-Iduronide is a common substrate for α-L-iduronidase catalytic activity.

Dianemycin (Nanchangmycin (free acid)) is a broad spectrum polyether antibiotic, inhibits gram-positive bacteria. Nanchangmycin is a broad spectrum antiviral active against Zika virus

GSK2983559 free acid is an effective and selective inhibitor of receptor-interacting protein 2 (RIP2). GSK2983559 free acid shows excellent activity in blocking many proinflammatory cytokine responses in human inflammatory bowel disease explant samples an

Mavodelpar free acid hydrochloride (Pparδ agonist HCl) is a potent PPARδ agonist.

AMI-1 free acid is a potent, cell-permeable, and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with inhibitory concentration 50 (IC50) values of 8.8 μM for human PRMT1 and 3.0 μM for yeast-Hmt1p. It achieves its PRMTs inhibitory activity by obstructing peptide-substrate binding [1].

AM095 (free acid) is a potent LPA1 receptor antagonist with IC50 values of 0.98 μM for recombinant human LPA1 and 0.73 μM for recombinant mouse LPA1.

Avibactam free acid is a potent β-lactamase inhibitor exhibiting covalent and reversible properties, capable of inhibiting TEM-1, P99, and CTX-M-15 at nanomolar concentrations. Avibactam free acid and Ceftazidime may be combined for treating urinary tract infections.

SSR128129E (free acid) is an orally available, allosteric inhibitor of FGFR, with an IC50 of 1.9 μM for FGFR1.

Dimesna (BNP-778), when used in conjunction with active cancer chemotherapy agents, can reduce the toxicity associated with uremia.

Monophosphoryl lipid A (free acid) acts as an agonist for toll-like receptor 4. It is employed in immunological and vaccine research.

3D-Monophosphoryl Lipid A-5 (free acid) is a TLR agonist used as an adjuvant in vaccines to enhance their immunogenicity.

Monophosphoryl Lipid A-12 (free acid) functions as a toll-like receptor 4 agonist, primarily utilized in immunology and vaccine research.

BNC105P is a benzo[b]furan-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and anti-tumor effects. Upon administration, BNC105P, in its disodium phosphate form, rapidly converts to BNC105. In activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may block spindle formation, cause cell cycle arrest, and dismantle the tumor vasculature. This creates a hypoxic environment, depriving tumor cells of nutrients, leading to apoptosis. Apart from its VDA activity, BNC105P also exerts direct cytotoxic effects on tumor cells by inhibiting tubulin polymerization. Notably, BNC105 is not a substrate for the multidrug-resistant P-glycoprotein (Pgp) transporter.

3D-Monophosphoryl Lipid (12,16) (3D-MPL (12,16)) free acid is a TLR agonist that serves as a vaccine adjuvant to boost the immunogenicity of vaccines.

Prostaglandin I2 is an unstable prostaglandin compound that inhibits platelet aggregation and induces vasodilation in the pulmonary vasculature via the "I prostanoid" (IP) receptor. AFP 07, a 7,7-difluoroprostacyclin derivative, serves as a selective and potent agonist for the IP receptor (Ki=0.561 nM). It exhibits weaker affinity for EP receptors, with a Ki value of > 100 nM for EP1-3 and > 10 nM for EP4. The compound 16(R)-AFP 07 free acid is an enantiomer of AFP 07. Its biological properties, particularly those involving IP and EP receptors, are yet to be fully assessed.

AFP 07 free acid is a 7,7-difluoroprostacyclin derivative. It also acts as a selective and highly potent agonist for the IP receptor.

Gastrazole is a CCK2 receptor antagonist potentially. It also used for the treatment of pancreatic cancer.

OSI-7904L is a folate-based thymidylate synthase inhibitor. It also has antimalarial and antitumor properties.

EC17 is a FITC conjugated folic acid, also known as Folate-FITC. It also acts as an FRα-targeting agent that fluoresces at 500nm. EC17 is a conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic acti

E-3030 free acid is a peroxisome proliferator-activated receptor (PPAR) agonist. E-3030 decreased blood glucose, triglyceride, non-esterified fatty acids, and insulin levels and increased blood adiponectin levels. Triglyceride- and non-high-density lipopr

FK-739 is an angiotensin type 1 receptor antagonist. FK 739 inhibits the specific binding of [125I]-angiotensin II to rat aortic smooth muscle cell membrane (IC50 = 8.6 nM) without displacing the specific binding of [125I]-angiotensin II to bovine cerebel

Fonsartan is an angiotensin receptor antagonist. Fonsartan inhibits the angiotensin II-induced trophic effects, fibronectin release and fibronectin-EIIIA+ expression in rat aortic vascular smooth muscle cells in vitro.